Erasca
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Company
Deck Type
IPO
Sector
Industry
Deck date
July 2021
Slide
27 of 46
Similar slides by Erasca
See diffirences between slides (animation)
Investor Presentation
January 2024
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Investor Presentation
November 2023
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Investor Presentation
August 2023
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Related slides by other companies
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase | RenovoRx
Aeglea BioTherapeutics
Investor Presentation
October 2023
cash and anticipated milestones | Aeglea BioTherapeutics
23andMe
Investor Day
January 2022
we have generated a research and development pipeline covering multiple therapeutic areas | 23andMe
BioAtla
Investor Presentation
August 2023
summary of dosing regimens for phase clinical studies with cab | BioAtla
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io